scholarly journals A Review of Current Management of Vitreomacular Traction and Macular Hole

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
Alfredo García-Layana ◽  
José García-Arumí ◽  
José M. Ruiz-Moreno ◽  
Lluís Arias-Barquet ◽  
Francisco Cabrera-López ◽  
...  
Keyword(s):  
Macular Hole ◽  
Treatment Options ◽  
Management Strategies ◽  
Posterior Vitreous Detachment ◽  
Treatment Algorithm ◽  
Vitreomacular Traction ◽  
Vitreomacular Adhesion ◽  
Current Management ◽  
Sequence Of Events ◽  
Therapeutic Algorithm

The paper presents a review of the sequence of events of posterior vitreous detachment (PVD), vitreomacular adhesion (VMA), vitreomacular traction (VMT), and macular hole (MH) from their pathophysiological aspects, clinical features, diagnostic implications, and current management strategies. A treatment algorithm to be used in clinical practice in patients with VMA, VMT, and MH based on the presence of symptoms, visual acuity, associated epiretinal membrane, and width of the vitreous attachment is presented. Observation, pharmacologic vitreolysis with ocriplasmin, and surgical treatment are positioned as treatment options in the different steps of the therapeutic algorithm, with clear indications of the paths to be followed according to the initial presenting manifestations and the patient’s clinical course.

scholarly journals Treatment of Vitreomacular Traction with Intravitreal Injection of Perfluoropropane

2020 ◽  
Vol 75 (4) ◽  
pp. 182-187
Author(s):  
Miroslav Veith
Keyword(s):  
Intravitreal Injection ◽  
Macular Hole ◽  
Retrospective Review ◽  
Gas Injection ◽  
Posterior Vitreous Detachment ◽  
Vitreomacular Traction ◽  
Outpatient Basis ◽  
Vitreomacular Adhesion ◽  
Vitreous Detachment

Purpose: To evaluate the effect of one intravitreal injection of expansile gas in the treatment of vitreomacular traction (VMT). Methods: A retrospective review of eyes with VMT treated with singl injection of 0,3 ml of 100% C3F8 gas was performed. The procedure was performed on an outpatient basis under topical anesthesia. Results: Twelve consecutive patient (14 eyes) with symptomatic VMT underwent pneumatic vitreolysis. Mean extend of vitreomacular adhesion was 490,5 µm (408-751). A posterior vitreous detachment developed in 13 eyes (92,9 %) after a single gas injection, in 11 eyes (84,6 %) during the first month of follow-up, in 2 eyes within two month of injection. Mean baseline and last BCVA were 0,5 (0,16-0,18) and 0,67 (0,2-1,0) respectively (p < 0,001). Mean folow-up time was 5,8 (1-16) months. The procedure was also successful in two eyes, which where previously unsuccessfuly treated with ocriplasmin. One eye formed a macular hole. There were no other complication. Conclucion: Intravitreal injection of C3F8 is an effective, safe and inexpensive therapy of vitreomacular traction.

Diagnosing and Treating Vitreomacular Adhesion

2011 ◽  
Vol 05 (01) ◽  
pp. 69 ◽  
Author(s):  
Paolo Carpineto ◽  
Luca Di Antonio ◽  
Agbeanda Aharrh-Gnama ◽  
Vincenzo Ciciarelli ◽  
Leonardo Mastropasqua ◽  
...  
Keyword(s):  
Posterior Vitreous Detachment ◽  
Standard Of Care ◽  
Age Related Macular Degeneration ◽  
Vitreomacular Traction ◽  
Vitreous Surgery ◽  
Vitreomacular Adhesion ◽  
Current Standard ◽  
Vitreous Detachment ◽  
Age Related ◽  
23 Gauge

Perifoveal vitreous detachment with residual vitreofoveal adhesion is considered as the first stage of posterior vitreous detachment. A key point is the transition from an innocuous vitreomacular adhesion (VMA) to a pathological vitreomacular traction (VMT). By using optical coherence tomography (OCT), VMA is defined as adhesion of the posterior hyaloid cortex involving the centre of the foveal region with or without a hyper-reflective signal on the inner surface of the retina. VMT is diagnosed when the inner macular surface slopes steeply, or sharp angulation and localised deformation of the retinal profile is detected at the VMA site. Otherwise, VMA is simply considered to be persistent adherence of the cortical vitreous. The tractional effects of perifoveal vitreous detachment cause a variety of macular pathologies determined by the size and the strength of the residual vitreoretinal adhesion. Vitreomacular adhesion plays a major role in the development of diseases such as vitreomacular traction syndrome (VMTS), macular hole, epiretinal membrane, tractional macular oedema and myopic macular retinoschisis. In addition, clinical evidence supports the theory that the course of diabetic retinopathy and age-related macular degeneration may be strongly influenced by an incomplete posterior vitreous separation. The current standard of care of vitreomacular interface pathologies is vitrectomy and membrane peeling – a procedure that is thought to relieve epiretinal traction – followed by regeneration of the retinal architecture and recovery of visual function. Over the last few years, with the introduction of 25-gauge (0.50mm) and 23-gauge (0.72mm) instruments, there has been another major shift toward transconjunctival microincisional vitrectomy surgery (MIVS). Pharmacological induction of posterior vitreous detachment (PVD) can become a further step toward a real ‘minimally invasive vitreous surgery’ for VMTS.

scholarly journals Epidemiology of Vitreomacular Interface Disorders

2018 ◽  
pp. 220-223
Keyword(s):  
Macular Hole ◽  
Epiretinal Membrane ◽  
Visual Loss ◽  
Disease Duration ◽  
Posterior Vitreous Detachment ◽  
Vitreomacular Adhesion ◽  
Membrane Formation ◽  
Vitreous Detachment ◽  
Vitreomacular Interface ◽  
Epidemiological Characteristics

Vitreomacular interface disorders consist of a series of diseases including vitreomacular adhesion, vitreomacular traction, macular hole, and epiretinal membrane formation. They occur due to the failed progression of normal posterior vitreous detachment. Affected patients may present with metamorphopsia and varying degrees of visual loss depending on the severity of foveal disturbance and disease duration. The aim of this review is to define the epidemiological characteristics of these groups of disorders which show an increased incidence and prevalence with age in parallel with the occurrence of posterior vitreous detachment.

scholarly journals Interprofessional Management of Allergic Conjunctivitis

2018 ◽  
Vol 80 (3) ◽  
pp. 11-27 ◽  
Author(s):  
C. Lisa Prokopich ◽  
Michael Lee-Poyb ◽  
Harold Kimc
Keyword(s):  
Daily Living ◽  
Allergic Conjunctivitis ◽  
Treatment Options ◽  
Management Strategies ◽  
Treatment Algorithm ◽  
Current Treatment ◽  
Inflammatory Drugs ◽  
Patient Presentation ◽  
Symptoms And Signs

Ocular allergies affect a large and increasing number of people in North America. Canada’s statistics are likely to mirror those of the U.S., where up to 40% of the population is affected by ocular allergies. The symptoms and signs of ocular allergies can greatly affect productivity and have a dramatic effect on overall quality of life (QoL). Over the years, many effective treatments have been developed for the management of ocular allergies. For allergic conjunctivitis, topical ophthalmic agents include antihistamines, mast-cell stabilizers, dual-activity agents, steroids, nonsteroidal anti-inflammatory drugs, and other immune-modulating drugs. Oral antihistamines are commonly chosen by patients for all forms of allergy, including allergic conjunctivitis. This review provides a summary of the forms of ocular allergy, with a particular focus on the symptoms and signs, diagnosis, current treatment options, and impact on QoL. More importantly, through multidisciplinary collaboration, a simplified treatment algorithm is proposed for Canadian clinical practice. This algorithm provides practitioners the best possible management strategies based on an individual patient presentation, thereby maximizing treatment efficacy and minimizing the effects on tasks of daily living and QoL.

The International Vitreomacular Traction Study Group Classification of Vitreomacular Adhesion, Traction, and Macular Hole

Ophthalmology ◽  
2013 ◽  
Vol 120 (12) ◽  
pp. 2611-2619 ◽  
Author(s):  
Jay S. Duker ◽  
Peter K. Kaiser ◽  
Susanne Binder ◽  
Marc D. de Smet ◽  
Alain Gaudric ◽  
...  
Keyword(s):  
Macular Hole ◽  
Group Classification ◽  
Vitreomacular Traction ◽  
Study Group ◽  
Vitreomacular Adhesion

Vitreomacular Traction: Pathophysiology, Classification, Clinical Diagnosis, and Treatment

2018 ◽  
pp. 249-255
Keyword(s):  
Eye Movements ◽  
Clinical Diagnosis ◽  
Posterior Vitreous Detachment ◽  
Diagnosis And Treatment ◽  
Wide Area ◽  
Vitreomacular Traction ◽  
Vitreomacular Adhesion ◽  
Vitreous Detachment ◽  
Foveal Detachment ◽  
Tractional Forces

Vitreomacular adhesions between the macula and the cortex may cause complications during the normal posterior vitreous detachment. These adhesions can affect a focal or wide area. Simple vitreomacular adhesion may not alter the macular anatomy. But sometimes these tractional forces can cause vitreomacular tractions with eye movements. This situation leads to distortion of the retina and foveal detachment. This review mentions the Vitreomacular Traction in the main aspects.

Relapsed/refractory Burkitt lymphoma and HIV infection

2017 ◽  
Vol 29 (7) ◽  
pp. 695-703
Author(s):  
Alina Khan ◽  
Amanda Brahim ◽  
Marco Ruiz ◽  
Neil Nagovski
Keyword(s):  
Stem Cell ◽  
Hiv Infection ◽  
Burkitt Lymphoma ◽  
Stem Cell Transplant ◽  
Treatment Options ◽  
Management Strategies ◽  
Cell Transplant ◽  
Current Management ◽  
New Therapies ◽  
The Future

The care of patients with HIV and Burkitt lymphoma poses a challenge to clinicians. Due to the limited treatment options that exist for relapsed/refractory Burkitt lymphoma, there is a need for the development of new therapies. This review aims to discuss evidence for current management strategies including chemotherapy and stem cell transplant, and highlight gaps in knowledge that will need to be addressed in the future.

Sign in / Sign up

Export Citation Format

Share Document